Article
Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant.
Blood - 25 Apr 2013
McIntosh Jenny, Lenting Peter J, Rosales Cecilia, Lee Doyoung, Rabbanian Samira, Raj Deepak, Patel Nishil, Tuddenham Edward G D, Christophe Olivier D, McVey John H, Waddington Simon, Nienhuis Arthur W, Gray John T, Fagone Paolo, Mingozzi Federico, Zhou Shang-Zhen, High Katherine A, Cancio Maria, Ng Catherine Y C, Zhou Junfang, Morton Christopher L, Davidoff Andrew M, Nathwani Amit C
Abstract excerpt
Recombinant adeno-associated virus (rAAV) vectors encoding human factor VIII (hFVIII) were systematically evaluated for hemophilia A (HA) gene therapy. A 5.7-kb rAAV-expression cassette (rAAV-HLP-codop-hFVIII-N6) containing a codon-optimized hFVIII cDNA in which a 226 amino acid (aa) B-domain spacer replaced the entire B domain and a hybrid liver-specific promoter (HLP) mediated 10-fold higher hFVIII levels in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
